Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2036. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2036
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2018 to 2043.
US 10,155,859
Polymer Composition for Forming a Melt-Extruded Film and Composites Thereof
Dec 3, 2036
US 11,690,807
Implantable Device for Sustained Release of a Macromolecular Drug Compound
May 20, 2039
US 11,951,215
Implantable Device for Sustained Release of a Macromolecular Drug Compound
no later than May 20, 2039
US 12,502,360
Implantable Device for Sustained Release of a Macromolecular Drug Compound
May 20, 2039
US 11,690,806
Implantable Device for Sustained Release of a Macromolecular Drug Compound
May 20, 2039
US 12,108,225
Implantable Device for Sustained Release of a Macromolecular Drug Compound
May 20, 2039
US 12,472,148
Implantable Device for Sustained Release of a Macromolecular Drug Compound
Sep 4, 2043
20232028203320382043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
17 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2039 · High confidence
Also notable
Ends May 2039 · High confidence
Also notable
Ends Aug 2038 · High confidence
Implantable Device for Sustained Release of a Macromolecular Drug Compound
US 11,690,807
The most cited patent in this portfolio, cited by 6 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Implantable Device for Sustained Release of a Macromolecular Drug Compound
US 11,690,806
Cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039.
Polymer Composition for Use in Cables
US 10,752,760
The earliest of the three still in force, granted 2020 and renewed since. Its term ends first, in 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 4, 2027
- 1 fee due Oct 9, 2027The maintenance fee for Implantable Device for Sustained Release of a Macromolecular Drug Compound (US 11,951,215) comes due Oct 9, 2027. Unpaid by Apr 10, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 4 largest of its 5 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Implantable Device for Sustained Release of a Macromolecular Drug Compound (2019) | 3 in force | to May 2039 |
| Implantable Device for Sustained Release of a Macromolecular Drug Compound (2019) | 2 in force | to May 2039 |
| Polymer Composition for Use in Cables | 2 in force | to Aug 2038 |
| Implantable Device for Sustained Release of a Macromolecular Drug Compound (2022) | 1 in force | to Sep 2043 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,155,859 | Polymer Composition for Forming a Melt-Extruded Film and Composites Thereof In force · High confidence | In force | High confidence | |
| US 11,352,486 | Polymer Composition for Use in Cables In force · High confidence | In force | High confidence | |
| US 10,752,760 | Polymer Composition for Use in Cables In force · High confidence | In force | High confidence | |
| US 11,690,806 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · High confidence | In force | High confidence | |
| US 11,690,807 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · High confidence | In force | High confidence | |
| US 11,951,215 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · Medium confidence | In force | Medium confidence | |
| US 12,108,225 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · High confidence | In force | High confidence | |
| US 12,502,360 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · Medium confidence | In force | Medium confidence | |
| US 12,472,148 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 17 applications pending · 10 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.